# Dose Optimization Study of Idelalisib in Follicular Lymphoma

> **NCT02536300** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 96 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02536300
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-14
- **Primary completion:** 2022-09-27
- **Final completion:** 2022-09-27
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** Gilead has made the decision to close the study due to enrollment challenges
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536300, "Dose Optimization Study of Idelalisib in Follicular Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02536300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*